TY - JOUR
T1 - A case of celecoxib-induced multiple ulcers of the small intestine observed on capsule endoscopy
AU - Aoyama, Yuki
AU - Takahashi, Sakuma
AU - Inaba, Tomoki
AU - Colvin, Mariko
AU - Ishikawa, Shigenao
AU - Wato, Masaki
AU - Kono, Yoshiyasu
AU - Kawano, Seiji
AU - Takaki, Akinobu
AU - Okada, Hiroyuki
PY - 2018/10
Y1 - 2018/10
N2 - The patient was a 75-year-old man with melena. Capsule endoscopy revealed colonic diverticular bleeding as well as 2-to 3-mm erosions scattered in the small intestine. The colonic diverticular bleeding was treated by endoscopic clipping. Two months later, administration of celecoxib was started for knee pain. Nine months later, black stools and iron-deficiency anemia were observed, and multiple ulcers were found in the intestine on capsule endoscopy. The patient was diagnosed as having nonsteroidal anti-inflammatory drug-induced small intestinal ulcer. The cele-coxib therapy was discontinued, and administration of misoprostol, rebamipide, and polaprezinc was started. Capsule endoscopy performed three months after starting the treatment demonstrated improvement of the ulcers. Celecoxib is a cyclooxygenase-2 (COX-2) selective inhibitor and is considered to confer a low risk of mucosal injury, but the risk of mucosal injury may increase with chronic administration of celecoxib or combination therapy with a proton pump inhibitor. Therefore, careful attention should be paid to patients who are being treated with celecoxib.
AB - The patient was a 75-year-old man with melena. Capsule endoscopy revealed colonic diverticular bleeding as well as 2-to 3-mm erosions scattered in the small intestine. The colonic diverticular bleeding was treated by endoscopic clipping. Two months later, administration of celecoxib was started for knee pain. Nine months later, black stools and iron-deficiency anemia were observed, and multiple ulcers were found in the intestine on capsule endoscopy. The patient was diagnosed as having nonsteroidal anti-inflammatory drug-induced small intestinal ulcer. The cele-coxib therapy was discontinued, and administration of misoprostol, rebamipide, and polaprezinc was started. Capsule endoscopy performed three months after starting the treatment demonstrated improvement of the ulcers. Celecoxib is a cyclooxygenase-2 (COX-2) selective inhibitor and is considered to confer a low risk of mucosal injury, but the risk of mucosal injury may increase with chronic administration of celecoxib or combination therapy with a proton pump inhibitor. Therefore, careful attention should be paid to patients who are being treated with celecoxib.
UR - http://www.scopus.com/inward/record.url?scp=85055492920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055492920&partnerID=8YFLogxK
U2 - 10.11280/gee.60.2297
DO - 10.11280/gee.60.2297
M3 - Article
AN - SCOPUS:85055492920
SN - 0387-1207
VL - 60
SP - 2297
EP - 2302
JO - Gastroenterological Endoscopy
JF - Gastroenterological Endoscopy
IS - 10
ER -